Title : Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning - Saifina_2022_Eur.J.Med.Chem_246_114949 |
Author(s) : Saifina LF , Abdalla M , Gubaidullina LM , Zueva IV , Eltayb WA , El-Arabey AA , Kharlamova AD , Lenina OA , Semenov VE , Petrov KA |
Ref : Eur Journal of Medicinal Chemistry , 246 :114949 , 2022 |
Abstract :
A series of new compounds in which uracil and 3,6-dimethyluracil moieties are bridged with different spacers were prepared and evaluated in vitro for the acetyl- and butyrylcholinesterase (AChE and BChE) inhibitory activities. These bisuracils are shown to be very effective inhibitors of AChE, inhibiting the enzyme at nano- and lower molar concentrations with extremely high selectivity for AChE vs. BChE. Kinetic analysis showed that the lead compound 2h acts as a slow-binding inhibitor of AChE and possess a long drug-target residence time (tau = 1/k(off) = 18.6 +/- 7.5smin). Moreover, compound 2h ameliorated muscle weakness in myasthenia gravis rat model with a lower effective dose and longer lasting effect than pyridostigmine bromide. Besides, it was shown that compound 2h has an effect of increasing efficiency of antidotal therapy as a pretreatment for poisoning by organophosphates. |
PubMedSearch : Saifina_2022_Eur.J.Med.Chem_246_114949 |
PubMedID: 36462442 |
Inhibitor | Bisuracil-pentylammonium-2h |
Saifina LF, Abdalla M, Gubaidullina LM, Zueva IV, Eltayb WA, El-Arabey AA, Kharlamova AD, Lenina OA, Semenov VE, Petrov KA (2022)
Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning
Eur Journal of Medicinal Chemistry
246 :114949
Saifina LF, Abdalla M, Gubaidullina LM, Zueva IV, Eltayb WA, El-Arabey AA, Kharlamova AD, Lenina OA, Semenov VE, Petrov KA (2022)
Eur Journal of Medicinal Chemistry
246 :114949